Phio Pharmaceuticals adds dermatologist R. Todd Plott to board
Phio expanded its board to six members effective July 20, 2026, naming Plott a director and a member of its Governance Committee.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) said effective July 20, 2026, its Board of Directors grew to six members with the appointment of R. Todd Plott, M.D., who will serve until the 2026 annual meeting of stockholders and who was also named to the Board's Governance Committee.1
According to the company, Plott is a dermatologist certified by his specialty board, with research and inventing credentials and past service on an FDA advisory committee, bringing more than 30 years in dermatologic care and innovation.1 The accompanying press release added detail on his background: he has contributed to development of treatments for acne and other skin conditions, and over his career he supervised numerous clinical trials, gaining experience in drug development, clinical research and patient care.1 The release also noted he currently practices privately, with a focus on complex skin diseases, acne and skin cancer1, and that he was a member of the FDA's Dermatologic and Ophthalmic Drug Advisory Committee between 2016 and 2021.1
CEO and Chairman Robert Bitterman said Plott's dermatology practice experience together with his clinical development background gives Phio a valuable resource as the company works to advance PH-762 for squamous cell carcinoma.1
The filing states Plott will enter into the company's standard indemnification agreement in connection with his board appointment,1 and will receive the standard compensation and equity awards given to non-employee directors.1 Phio also disclosed there are no arrangements or understandings with any other parties related to his appointment,1 and no current or proposed transactions between the company and Plott or his immediate family requiring disclosure under Regulation S-K Item 404(a).1
Phio describes itself as a clinical-stage biopharmaceutical company developing its proprietary INTASYL siRNA gene silencing technology, with lead candidate PH-762 designed to silence the PD-1 gene implicated in several skin cancers.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.